Even in successfully edited clones, pathogenic DUX4 levels are reduced, but not silenced, likely due to compensation by a cryptic PAS; the authors concluded that this is not a viable therapeutic strategy for FSHD [77]. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.